Blar i forfatter Det helsevitenskapelige fakultet "Holme, Pål Andre"

Viser treff 1-3 av 3

    • Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. 

      Barratt-Due, Andreas; Fløisand, Yngvar; Lang, Hilde Elisabeth; Kvam, Ann Kristin; Holme, Pål Andre; Bergseth, Grete; Tjønnfjord, Geir Erland; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-04-22)
      Catastrophic antiphospholipid syndrome is associated with excessive complement activation explaining the clinical efficacy of complement inhibitory treatment.

    • Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study 

      Schultz, Nina Haagenrud; Søraas, Arne Vasli; Sørvoll, Ingvild Hausberg; Akkøk, Cigdem Ahaein; Vetlesen, Annette; Bhamra, Jagjit Singh; Ahlen, Maria Therese; Holme, Pål Andre; Aamodt, Anne Hege; Skagen, Karolina Ryeng; Skattør, Thor Håkon; Skjelland, Mona; Wiedmann, Markus (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-17)
      Objectives Fatal complications have occurred after vaccination with ChAdOx1 nCoV-19, a vaccine against Covid-19. Vaccine-induced immune thrombotic thrombocytopenia (VITT) with severe outcome is characterized by venous thrombosis, predominantly in cerebral veins, thrombocytopenia and anti-PF4/polyanion antibodies. Prolonged headaches and cutaneous hemorrhages, frequently observed after the ChAdOx1 ...

    • Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series 

      Wiedmann, Markus; Skattør, Thor Håkon; Stray-Pedersen, Arne; Romundstad, Luis Georg; Antal, Ellen-Ann; Marthinsen, Pål Bache; Sørvoll, Ingvild Hausberg; Ernstsen, Siw Leiknes; Lund, Christian G.; Holme, Pål Andre; Johansen, Tonje Okkenhaug; Brunborg, Cathrine; Aamodt, Anne Hege; Schultz, Nina Haagenrud; Skagen, Karolina Ryeng; Skjelland, Mona Elisabeth (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-07-30)
      During a 2-week period, we have encountered five cases presenting with the combination of cerebral venous thrombosis (CVT), intracerebral hemorrhage and thrombocytopenia. A clinical hallmark was the rapid and severe progression of disease in spite of maximum treatment efforts, resulting in fatal outcome in for 4 out of 5 patients. All cases had received ChAdOx1 nCov-19 vaccine 1–2 weeks earlier and ...